What is the main purpose of this 8-K filing?

This 8-K filing announces Abbott Laboratories' financial results for the fourth quarter and full year of 2024, primarily referencing a press release containing these details.

What are non-GAAP financial measures and why does Abbott use them?

Abbott uses non-GAAP financial measures to exclude certain items that management considers unusual or unpredictable, such as acquisition/divestiture costs, restructuring expenses, and intangible amortization. The company believes these measures provide a better understanding of its ongoing business performance.

What should investors be aware of regarding Abbott's use of non-GAAP measures?

Abbott cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). This means investors should look at both GAAP and non-GAAP figures for a complete picture.

Where can I find the detailed financial results?

The detailed financial results are provided in the press release issued by Abbott on January 22, 2025, which is furnished as Exhibit 99.1 to this 8-K filing.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) has filed an 8-K report on January 22, 2025, announcing its financial results for the fourth quarter and full year 2024. The report primarily references a press release (Exhibit 99.1) that details these results. Investors should note that Abbott utilizes non-GAAP financial measures to present its performance, adjusting for items such as acquisition and divestiture expenses, restructuring costs, fair value adjustments, impairment charges, regulatory costs, tax-related adjustments, and intangible amortization. The company states that these non-GAAP measures offer better insight into ongoing business performance as assessed by management, but investors are cautioned to consider them alongside GAAP measures.

Key Highlights

1Abbott Laboratories reported its Q4 and full-year 2024 financial results on January 22, 2025.
2The results are detailed in a press release furnished as Exhibit 99.1.
3The company employs non-GAAP financial measures for performance reporting.
4Non-GAAP adjustments include expenses related to acquisitions, divestitures, restructuring, and impairments.
5Other adjustments comprise fair value changes, regulatory costs, tax benefits/expenses, and intangible amortization.
6Abbott's management believes non-GAAP measures provide a clearer view of ongoing operational performance.
7Investors are advised to review non-GAAP measures in conjunction with GAAP-compliant financial data.

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 22, 2025)

Summary

Key Highlights

Frequently Asked Questions